| Name | Title | Contact Details |
|---|
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
Oncolytics Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.